EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
|Poll|May 14, 2015
Morbidly Obese Man With Abdominal Wall Cellulitis
Author(s)Eve J. Lowenstein, MD, PhD
What’s the underlying cause of current cellulitis in this morbidly obese man?
Advertisement
A morbidly obese man (weight over 400 lb) with multiple medical comorbidities and a long history of extensive psoriasis is hospitalized for the third time for cellulitis of the abdominal wall. The skin of the wall is rock hard, with pebbly nodularity of the surface.
What underlying skin condition on the belly is predisposing to recurrent abdominal cellulitis?
Advertisement
Related to this article
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Grants Breakthrough Device Designation to Natera's Multi-Cancer Early Detection Blood Test
2
Who Should Get a CGM? Expanding the Primary Care Candidate Pool
3
Most Adolescents With Colorectal Cancer Diagnosed at Advanced Stage, Study Finds
4
PrEP Deserts: Why HIV Prevention Still Misses Those at Risk
5